Cortex Pharmaceuticals (RSPI) Stock Price, News & Analysis

Company Overview

Cortex Pharmaceuticals, Inc. (OTCMKTS: RSPI) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system (CNS) disorders. The company’s drug discovery efforts center on positive allosteric modulators of AMPA receptors, which have the potential to enhance synaptic transmission and support cognitive function. Cortex’s lead candidate, CX-717, has been studied for applications in attention deficit hyperactivity disorder, respiratory stimulation, and age-related memory decline. The company’s research platform integrates medicinal chemistry, pharmacology and translational neuroscience to advance compounds through preclinical and clinical development.

Over its history, Cortex Pharmaceuticals has established strategic collaborations with academic research centers and contract research organizations to accelerate the clinical evaluation of its pipeline candidates. In addition to its U.S. headquarters in Irvine, California, the company maintains relationships with European research sites to support multi‐center clinical trials. Cortex has also engaged in partnerships to explore combination therapies and formulation improvements aimed at optimizing delivery and patient compliance. Through these alliances, Cortex seeks to expand the potential therapeutic applications of its proprietary modulators.

Founded in 1996, Cortex Pharmaceuticals has navigated the challenges of early-stage drug development by leveraging a focused scientific approach and opportunistic licensing agreements. The company’s executive team brings together seasoned professionals with experience in neuroscience, regulatory affairs and pharmaceutical operations. Cortex’s leadership is supported by a board of directors and scientific advisors with deep expertise in CNS pharmacology and commercial strategy. Together, they are committed to advancing the company’s clinical programs and delivering potential treatment options for patients with cognitive and neurological disorders.

Key Stats

• Today's Range: $0.0010 to $0.0015
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0027
• Volume: 1.47 million shs
• Average Volume: 380,850 shs
• Market Capitalization: $1.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RSPI Stock Analysis - Frequently Asked Questions

How have RSPI shares performed this year?

Cortex Pharmaceuticals' stock was trading at $0.0008 on January 1st, 2025. Since then, RSPI shares have increased by 37.5% and is now trading at $0.0011.

How were Cortex Pharmaceuticals' earnings last quarter?

Cortex Pharmaceuticals Inc. (OTCMKTS:RSPI) released its quarterly earnings data on Wednesday, August, 19th. The company reported ($0.01) EPS for the quarter.

How do I buy shares of Cortex Pharmaceuticals?

Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cortex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortex Pharmaceuticals investors own include American Bio Medica (ABMC), Galaxy Next Generation (GAXY), Asia Broadband (AABB), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET) and AMC Entertainment (AMC).

Company Calendar

• Last Earnings: 8/19/2020
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RSPI
• CIK: 849636
• Web: www.respirerx.com
• Phone: (201) 444-4947
• Fax: 949-727-3657
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 949,460,000
• Free Float: 474,447,000
• Market Cap: $1.04 million
• Optionable: Not Optionable
• Beta: 0.14